CMS opens coverage analysis on MR angiography
This article was originally published in The Gray Sheet
Executive Summary
Medicare agency opens 30-day comment period on Oct. 7 for an internally-generated national coverage analysis of magnetic resonance angiography (MRA), a magnetic resonance imaging procedure for visualization of blood flow and diseased vessels. CMS recently lifted the national non-coverage status for MRI for blood flow, leaving decisions on MRA in the hands of local Medicare contractors. The agency seeks comments on the long- and short-term clinical outcomes of MRA for indications that remain non-covered in the Medicare population. Comments are due Nov. 6, and CMS plans to issue a final decision by July 6, 2010
You may also be interested in...
CMS merges coverage for magnetic resonance angiography and MRI
Medicare agency finalizes its decision memo June 3 on magnetic resonance angiography, a specific application of magnetic resonance imaging used for blood flow determination, consolidating provisions under a single national coverage determination. The decision eliminates certain non-coverage language for MRA, but leaves most coverage decisions to the discretion of local contractors. CMS opened the coverage determination last October (1"The Gray Sheet" Oct. 12, 2009)
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.